Region: Kingdom of Saudi Arabia (KSA)

Source: Regional Health Economics Expert & Clinical Pharmacist

The Challenge: Turning Regulatory Complexity into Commercial Clarity

For pharmaceutical manufacturers operating in Saudi Arabia,Loss of Exclusivity (LoE) presents a unique set of regulatory and commercial challenges distinct from European or North American markets.

Our recent interaction with a Riyadh-based Health Economics expert, specializing in value-based agreements and government formulary management, provided insights on strategic approaches for a rare disease brands approaching patent expiry. They revealed that while standard managed entry agreements (MEAs) are not explicitly designed to block generics, the mechanics of Saudi hospital formularies and the rise of the Local Content Authority offer robust avenues for brand protection.

The “Registration Gap”

Global partners often stumble on a critical assumption: that a global patent automatically secures protection in the Kingdom. It doesn’t.

There is a 12 to 18-month window to register the global patent specifically with the Saudi Authority for Intellectual Property. Missing this step can open the market for a generic competitor legally within a year even if the global exclusivity is still active.

“If a company fails to register the patent locally, a generic can potentially enter the market within one year, even before global patent exclusivity is lost.”

Unlike the EMA, the Saudi Food and Drug Authority (SFDA) protection is strictly patent-based. If the local paperwork isn’t filed, the SFDA has no legal ground to delay a generic approval. Ensuring local patent hygiene is critical.

Managed Entry Agreements as Defensive Moats

While a life sciences company cannot sign an agreement specifically to block generics, the operational reality of Saudi hospitals offers a different form of protection.

Government hospitals generally prefer maintaining a single product per molecule creating a de facto “moat” for brands with active contracts.

Contract Continuity: A multi-year Managed Entry Agreement (MEA), such as a 3-year outcome or volume-based deal, when executed before the generic market entry. This proactive agreement typically results in the institution continuing to utilize the original drug given minimum volume requirements.

“Once a contract is signed, the institution will typically stick with the product… because including [a generic] would affect the volume commitments of the existing signed contract.”

Securing a multi-year value-based agreement before the generic launch effectively locks out competition for the duration of the contract, turning a commercial agreement into a defensive shield.

Localization: The Strongest Defense

On-the-ground expertise confirms that Localization and Investment are the most effective strategies for protecting market share against lower-priced competitors. This is driven by the Local Content and Government Procurement Authority.

Binding Tender Commitments: Companies that invest in local manufacturing or packaging receive significant prioritization (10% to 30% preference). In some cases, this results in a binding commitment from tenders (such as NUPCO) to purchase the localized brand, even if a generic competitor is significantly cheaper.

Investment Thresholds: Foreign companies with sales exceeding 100 million SAR have mandatory investment targets (35% of sales), smaller brands can also voluntarily engage with the Local Content Authority.

Localization isn’t just a compliance box to check; it’s a strategic asset. A brand’s willingness to invest locally typically outweighs the price advantage of incoming generics.

Smart Pricing Dynamics

When protecting price integrity, the market favors specific, grounded mechanisms.

FOC over Discounts: Hospitals accept “Free of Charge” goods (bonus units) readily allowing the brand to offer an effective discount to the hospital without lowering the unit price used for International Reference Pricing (IRP). In high-volume areas like diabetes, FOC rates can exceed 100%, though for rare diseases, FOC is usually embedded within a broader MEA.

Prepare for the Drop: Upon the entry of the first generic, the SFDA mandates an immediate price reduction for the originator (20% for Biologics, 25% for Chemical Entities). While regulations state this drop happens immediately upon generic registration, the expert noted that administrative latency (“human error”) can sometimes delay this enforcement by a few months, providing a brief window of preserved revenue.

The Path Forward

Navigating LoE in Saudi Arabia requires a decisive, three-pillared approach:

1. Validating local patent registration immediately
2. Securing formulary exclusivity through multi-year MEAs before competitors arrive
3. Engaging with the Local Content Authority to turn local investment into long-term traction

At Becoya, we help you turn these complexities into confident decisions, ensuring your therapy maintains its momentum in the region.